“Is Ozempic a peptide?” is one of the most common questions patients bring into a consult, and the honest answer is more useful than a yes or a no.
Yes — semaglutide is a peptide. So is tirzepatide. So is insulin, and so is the sermorelin your colleague down the hall has been prescribing for a decade. The word “peptide” describes a chemical class, not a category of treatment, and that single fact clears up most of the confusion that follows.
The confusion matters clinically, because patients routinely assume that if Ozempic is a peptide and BPC-157 is a peptide, the two must be comparably studied, comparably regulated, and comparably safe to obtain. They are not remotely comparable on any of those axes.
What a peptide actually is
A peptide is a short chain of amino acids. Chains longer than roughly fifty amino acids are generally called proteins; shorter chains are peptides. That is the whole definition. It says nothing about what a molecule does, whether it works, or whether it is legal to prescribe.
Your body makes thousands of them. Insulin is a peptide hormone. So are glucagon, oxytocin, and growth hormone-releasing hormone. When a pharmaceutical company develops a peptide drug, it is usually building an analog of one of these — modified to resist enzymatic breakdown so it lasts long enough to dose weekly rather than hourly.
So is Ozempic a peptide?
Yes. Semaglutide, the active ingredient in Ozempic and Wegovy, is a synthetic analog of GLP-1, a naturally occurring incretin peptide. It has been structurally modified — including a fatty-acid chain that binds albumin — so that it survives in circulation long enough for once-weekly subcutaneous dosing.
Tirzepatide, the active ingredient in Mounjaro and Zepbound, is also a peptide, and a dual agonist at the GIP and GLP-1 receptors. Both are FDA-approved. Both went through full clinical development. Both are prescribed and dispensed through ordinary pharmacy channels.
The distinction that actually matters
If “peptide” does not tell you anything useful about a molecule, what does? Three things, and they are the questions worth teaching your patients to ask:
- Is it an FDA-approved drug? Semaglutide and tirzepatide are. Sermorelin, PT-141 as Vyleesi, and teriparatide are examples of approved peptide drugs in other categories. BPC-157, TB-500, epithalon and most of the peptides discussed in wellness settings are not.
- What is the evidence base? Approved peptides carry phase-three human trial data. Many popular compounded and research peptides rest on preclinical and animal work, small uncontrolled human studies, or both. That is a difference in kind, not degree.
- How is it obtained? An approved drug comes from a pharmacy against a prescription. An unapproved peptide either comes from a compounding pharmacy operating under specific federal rules, or it comes from a research-chemical website that is not a pharmacy at all.
A patient who understands those three questions will never again ask whether Ozempic and a vial bought online are “the same kind of thing.”
Where growth-hormone peptides fit
The category patients most often conflate with GLP-1 drugs is the growth hormone secretagogues — sermorelin, ipamorelin, CJC-1295, tesamorelin, and the oral compound MK-677.
These work on an entirely different axis. GLP-1 receptor agonists act on incretin signaling, appetite, and gastric emptying. Secretagogues stimulate endogenous growth hormone release through the GHRH or ghrelin receptor pathways. They are not weight-loss drugs in the sense patients mean, their body-composition effects are considerably more modest than the incretin class, and their regulatory positions differ from one another substantially. Sermorelin and tesamorelin have approval histories; several others do not, and some secretagogues remain restricted from routine 503A compounding.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Medical Weight Loss & Metabolic Health courses — live patients, expert faculty, and ongoing mentorship.
Treating the secretagogue class as interchangeable — clinically or legally — is one of the more common errors in this space.
Why patients get this wrong
Because the marketing is deliberately blurry. A website selling unapproved compounds benefits enormously from the association with a drug that made headlines for producing twenty percent weight loss in trials. Calling both “peptide therapy” borrows credibility from the approved end of the category and lends it to the unapproved end.
The clinician’s job is to unbundle that. Not by dismissing peptides — the category contains genuinely important approved drugs and genuinely promising investigational ones — but by being precise about which is which.
Frequently asked questions
Is Ozempic a peptide?
Yes. Semaglutide is a synthetic analog of the GLP-1 incretin peptide, modified for once-weekly dosing. It is an FDA-approved drug.
Is peptide therapy the same as taking Ozempic?
No. “Peptide therapy” is an umbrella term covering everything from approved drugs to unapproved research compounds. Semaglutide is at the approved, trial-supported end. Much of what is marketed as peptide therapy is not.
Is tirzepatide a peptide?
Yes, and it is a dual agonist at the GIP and GLP-1 receptors. It is FDA-approved.
Are growth hormone peptides the same as GLP-1 drugs?
No. They act on different receptor systems, produce different effects, have different evidence bases, and sit in different regulatory positions.
Is insulin a peptide?
Yes. Insulin is a peptide hormone, which is a useful reminder that the word describes chemistry rather than a treatment philosophy.
Are all peptides unregulated?
No. Approved peptide drugs are regulated exactly like any other prescription drug. Unapproved peptides sit under compounding law, and many cannot currently be compounded legitimately at all.
Teach the distinction, then train for it
Empire’s Advanced Weight Management Certification covers the incretin class in clinical depth, and the Empire Peptide Therapy Certification covers the wider category — including the regulatory framework that separates an approved drug from a compounded preparation from a research chemical.
Compound references: semaglutide, tirzepatide, sermorelin and growth hormone peptides in the Peptide Therapy Resource Center.
